JP2009513564A - Ｒｎａ依存性ｒｎａウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体 - Google Patents

Ｒｎａ依存性ｒｎａウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体 Download PDF

Info

Publication number
JP2009513564A
JP2009513564A JP2008526091A JP2008526091A JP2009513564A JP 2009513564 A JP2009513564 A JP 2009513564A JP 2008526091 A JP2008526091 A JP 2008526091A JP 2008526091 A JP2008526091 A JP 2008526091A JP 2009513564 A JP2009513564 A JP 2009513564A
Authority
JP
Japan
Prior art keywords
alkyl
amino
hydrogen
compound
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008526091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513564A5 (cg-RX-API-DMAC7.html
Inventor
ブートラ，ガボール
コープリンガー，ケネス・アラン
マツコス，マルコム
マクマスターズ，ダニエル・アール
オルセン，デイビツド・ビー
ヤン，リフー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2009513564A publication Critical patent/JP2009513564A/ja
Publication of JP2009513564A5 publication Critical patent/JP2009513564A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2008526091A 2005-08-09 2006-08-04 Ｒｎａ依存性ｒｎａウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体 Withdrawn JP2009513564A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70670805P 2005-08-09 2005-08-09
PCT/US2006/030549 WO2007021610A2 (en) 2005-08-09 2006-08-04 Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection

Publications (2)

Publication Number Publication Date
JP2009513564A true JP2009513564A (ja) 2009-04-02
JP2009513564A5 JP2009513564A5 (cg-RX-API-DMAC7.html) 2009-09-24

Family

ID=37758066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008526091A Withdrawn JP2009513564A (ja) 2005-08-09 2006-08-04 Ｒｎａ依存性ｒｎａウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体

Country Status (6)

Country Link
US (1) US7632821B2 (cg-RX-API-DMAC7.html)
EP (1) EP1915054A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009513564A (cg-RX-API-DMAC7.html)
AU (1) AU2006280175B2 (cg-RX-API-DMAC7.html)
CA (1) CA2618560A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007021610A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150002844A (ko) * 2012-04-18 2015-01-07 바이오크리스트파마슈티컬즈,인코포레이티드 바이러스 폴리머라아제를 억제하기 위한 조성물 및 방법
JP2023553243A (ja) * 2021-12-16 2023-12-21 アスカレシス バイオサイエンス カンパニー リミテッド ヌクレオシド誘導体及びその使用方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US8242085B2 (en) 2007-05-10 2012-08-14 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
NZ706985A (en) 2012-10-08 2018-08-31 Centre Nat Rech Scient 2’-chloro nucleoside analogs for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EP4667053A2 (en) 2015-03-06 2025-12-24 ATEA Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
SMT202200072T1 (it) 2016-09-07 2022-03-21 Atea Pharmaceuticals Inc Nucleotidi purinici 2'-sostituiti-n6-sostituiti per il trattamento dei virus rna
FI3577124T3 (fi) 2017-02-01 2025-02-13 Atea Pharmaceuticals Inc Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134154A (en) * 1989-10-20 1992-07-28 Merrell Dow Pharmaceuticals Inc. Phenoxy-heterocyclic compounds
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
HUP0004853A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AR031905A1 (es) 2000-12-12 2003-10-08 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
JP3954573B2 (ja) * 2002-04-22 2007-08-08 松下電器産業株式会社 磁気抵抗効果素子とこれを用いた磁気ヘッドおよび磁気メモリならびに磁気記録装置
JP2005530759A (ja) * 2002-05-06 2005-10-13 ジェネラブズ テクノロジーズ インコーポレーティッド Ｃ型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体
EP1773355B1 (en) * 2004-06-24 2014-06-25 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150002844A (ko) * 2012-04-18 2015-01-07 바이오크리스트파마슈티컬즈,인코포레이티드 바이러스 폴리머라아제를 억제하기 위한 조성물 및 방법
JP2015514772A (ja) * 2012-04-18 2015-05-21 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ウイルスポリメラーゼを阻害するための組成物および方法
JP2018111692A (ja) * 2012-04-18 2018-07-19 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ウイルスポリメラーゼを阻害するための組成物および方法
KR102156819B1 (ko) 2012-04-18 2020-09-16 바이오크리스트파마슈티컬즈,인코포레이티드 바이러스 폴리머라아제를 억제하기 위한 조성물 및 방법
JP2023553243A (ja) * 2021-12-16 2023-12-21 アスカレシス バイオサイエンス カンパニー リミテッド ヌクレオシド誘導体及びその使用方法
JP7504517B2 (ja) 2021-12-16 2024-06-24 アスカレシス バイオサイエンス カンパニー リミテッド ヌクレオシド誘導体及びその使用方法

Also Published As

Publication number Publication date
AU2006280175A1 (en) 2007-02-22
WO2007021610A2 (en) 2007-02-22
CA2618560A1 (en) 2007-02-22
AU2006280175B2 (en) 2011-09-01
US20090099126A1 (en) 2009-04-16
EP1915054A2 (en) 2008-04-30
WO2007021610A3 (en) 2007-10-04
US7632821B2 (en) 2009-12-15
EP1915054A4 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
US7632821B2 (en) Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
AU2005267421B2 (en) Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US8071568B2 (en) Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
EP2120565B1 (en) Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US20080280842A1 (en) Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
US20120010164A1 (en) Antiviral agents
HUP0400726A2 (hu) Nukleozid-származékok, mint az RNS-függő RNS-vírus-polimeráz inhibitorai
EP1758453A2 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
CN101896497A (zh) 抗病毒剂
CA2490666A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090724

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120426